Discover essential products for nonclinical safety and toxicology in drug development.

Discover products related to FDA and EMA guidelines in safety assessment.

Discover essential products for navigating the toxicology regulatory landscape.

Discover products that support nonclinical safety and toxicology in drug applications.

Discover products to support your nonclinical study reports and drug development.

Discover products that support nonclinical safety in drug development.

Discover products that support your knowledge of regulatory agencies in drug development.

Discover products that support your knowledge of GLP standards in drug development.

Discover products that can deepen your insights into toxicology and regulatory approval.

Most nonclinical teams spend a lot of time thinking about which studies to run. Very few spend enough time thinking about when. Study sequencing is one of the most consequential — and most underestimated — decisions in IND-enabling development. Get the order right and your program builds on itself. Get it wrong and you're defending conclusions built on shaky ground. This issue breaks down the 3 sequencing mistakes I see most often.

"No major findings" is one of the most reassuring phrases in nonclinical development — and one of the most dangerous. It describes what wasn't observed. It doesn't interpret what the study actually resolved. Once that phrase enters the conversation, attention shifts, assumptions harden, and questions stop being asked. This issue unpacks why clean studies require more interpretation, not less.